Abstract:Objective:To investigate the effect of Kirsten rat sarcoma virus oncogene homolog (KRAS) mutation subtype on the expression of programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2) in non-small cell lung cancer cells.Methods:A total of 95 KRAS-positive non-small cell lung cancer patients who were admitted to Gansu Cancer Hospital from January 2018 to January 2021 were enrolled. KRAS genome sequence was detected by sequencing, and the expression of PD-L1 and PD-L2 was detected by real-time fluorescent quantitative polymerase chain reaction (PCR) and western blotting. The clustered regularly interspaced short palindrome repetitive gene editing (CRISPR/CAS9) technology were used to construct KRAS-deficient A549 cells. The KRAS wild type and mutant were overexpressed in knockout strain, and its effect on PD-L1 and PD-L2 Expression were detected. The wild-type and mutant KRAS overexpressed KRAS knockout human alveolar epithelial cell line 549 (A549) was compared with dendritic cells and cytokine induced killer cells (DC-CIK). The apoptotic level of cluster determinant 3 positive (CD3 +) cells was detected by flow cytometry. The t test was used to compare continuous variables. The Mann-Whitney test was used to analyze the PD-L1 and PD-L2 of KRAS mutant patients. The chi-square test was used to analyze the clinical characteristics of KRAS mutant and KRAS wild-type in patients with non-small cell lung cancer. Results:95 cases of KRAS-positive non-small cell lung cancer patients, 31 cases of KRAS wild type, and 64 cases of KRAS mutant type were included. Among them, 13 cases of KRAS glycine mutation were mutated to aspartic acid (G12D), 12 cases were mutated to valine (G12V), 25 cases were mutated to cysteine (G12C), and 14 cases were mutated to alanine (G12A). The mRNA expression levels of PD-L1 and PD-L2 in patients with KRAS mutation and protein expression levels were higher than those of KRAS wild type patients (1.062 vs. 1.834, U=38; 1.062 vs. 1.668, U=70; 1.062 vs. 1.544, U=111; 1.062 vs. 1.479, U=89, P<0.05; 1.067 vs. 1.798, U=68; 1.067 vs. 1.595, U=86; 1.067 vs. 1.527, U=171; 1.067 vs. 1.680, U=34, P<0.05), and the differences were statistically significant. In the KRAS knockout A549 cell line, compared to the KRAS wild type, the KRAS mutant type was more able to promote the expression of PD-1 ligands PD-L1 and PD-L2. At the same time, KRAS-G12D, KRAS-G12V, KRAS-G12C, KRAS-G12A plasmids were mixed together as RAS wild-type (KRAS-MT) and KRAS mutant (KRAS-WT) to transfect KRAS knockout A549 cell lines, KRAS-MT can still promote PD-1 ligand PD-L1 And PD-L2 expression. After overexpressing KRAS-MT and KRAS-WT in the KRAS knockout A549 cell line, the KRAS mutant subtype cannot activate the extracellular signal-regulated kinase (ERK) pathway, but can activate the serine-threonine protein Serine-Threonine Protein Kinase (AKT) pathway. After treatment with AKT inhibitor, there was no significant difference in the expression of PD-L1 and PD-L2 in KRAS knockout A549 cell lines transfected with KRAS-MT and KRAS-WT. The KRAS KO A549 cell line transfected with KRAS-MT or KRAS-WT was co-cultured with DC-CIK at a ratio of 1∶1, and then the apoptosis level of DC-CIK cells was detected. It was found that KRAS-MT can significantly increase DC-CIK. The apoptosis of CD3 + cell subsets in CIK cells ( F=12.5, P<0.05), and the difference was statistically significant; however, KRAS-MT and KRAS-WT paired with AKT inhibitors. There was no statistically significant difference in the effect of CD3 + cell subsets on apoptosis in DC-CIK cells ( P>0.05). Conclusion:KRAS mutant subtypes can significantly enhance the expression of PD-1 ligands PD-L1 and PD-L2 in non-small cell lung cancer cells, and can promote the apoptosis of CD3 + cell subsets in immune cells DC-CIK cells.

KRAS Mutants to Regulate PD-L1 Expression Through NF-ƘB and HIF-1α Pathways in Non-Small Cell Lung Cancer Cells.

KRAS Mutation Subtypes Responded Differently to Combination Immunotherapy Via Disturbing Myeloid-Derived Suppressor Cells in Non-Small Cell Lung Cancer.

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer

Hypoxia‐inducible Factor‐1α and Nuclear Factor‐κb Play Important Roles in Regulating Programmed Cell Death Ligand 1 Expression by Epidermal Growth Factor Receptor Mutants in Non‐small‐cell Lung Cancer Cells

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Advances of the relationship between PD-1/PD-L1 pathway and KRAS gene mutation in non-small cell lung cancer

[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].

Unveiling the role of KRAS in tumor immune microenvironment

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling

Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T‐Cells to Activation‐Induced Cell Death in Colorectal Cancer

KRAS G12D Mutation Predicts Lower TMB and Drives Immune Suppression in Lung Adenocarcinoma.

PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.

Tailored modulation of stemness and drug resistance marker characteristics in K-Ras mutant lung cancer cells via PD-L1 gene suppression

Effects of mutation subtypes of kirsten rat sarcoma viral oncogene homolog on the expression of programmed cell death ligands 1 and 2 in non-small cell lung cancer cells

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

An Integrative Pharmacogenomics Analysis Identifies Therapeutic Targets in KRAS-Mutant Lung Cancer

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.